Roche reloads B-cell strategy with $1.53B Simcere deal
Roche has licensed Simcere Zaiming’s preclinical trispecific antibody SIM0660, paying $75 million (€65 million) upfront in a deal potentially worth $1.53 billion (€1.32 billion).
Why it matters: The Swiss pharma is doubling down on therapies that achieve deeper B-cell depletion, an increasingly competitive strategy spanning blood cancers and autoimmune diseases — just weeks after Roche abandoned another T-cell engager it had been testing in lupus.
Zoom in: Roche receives exclusive worldwide rights to develop, manufacture and commercialize SIM0660. Simcere is eligible for development, regulatory and commercial milestones, taking total payments to $1.53 billion, plus tiered royalties reaching double-digit percentages.
How it works: The antibody simultaneously targets CD79a and CD19 on B cells while engaging CD3 on T cells, redirecting the immune cells to kill the targeted B cells.
- The idea behind hitting two B-cell markers is to broaden the population of cells that can be eliminated, potentially including cells that escape therapies targeting a single antigen. Simcere also designed the molecule to limit cytokine release, a major safety concern with T-cell engagers.
Backstory: Roche already has considerable experience targeting B cells. Its portfolio includes anti-CD20 antibodies Gazyva and Rituxan/MabThera, as well as approved CD20xCD3 T-cell engagers Lunsumio and Columvi for B-cell cancers.
- The company is also pushing B-cell depletion deeper into autoimmune disease. Gazyva is under regulatory review for systemic lupus erythematosus after a positive Phase 3 trial, while Roche has identified B-cell-depleting bispecific antibodies and allogeneic CAR-T therapies among its immunology pipeline priorities.
Yes, but: Roche recently learned how difficult translating the T-cell engager approach into autoimmune disease can be. In July, it discontinued RG6382, a CD19xCD3 bispecific being studied in Phase 1 lupus patients, after concluding the molecule lacked the characteristics needed to advance in that indication.
- SIM0660 therefore gives Roche another — potentially broader — way of pursuing deep B-cell depletion. But the companies have not disclosed which diseases Roche plans to test first, and the asset has yet to enter human trials.
Big picture: The agreement is also the latest validation of Simcere’s growing role as a source of assets for Western pharma. The Chinese group says it has now completed six out-licensing transactions carrying more than $6.1 billion in potential payments. Those deals include:
- AbbVie’s $1.05 billion pact for the Phase 1 trispecific T-cell engager SIM0500
- NextCure’s $745 million agreement for ex-China rights to the Phase 1 antibody-drug conjugate SIM0505
- Ipsen’s $1.06 billion deal for the preclinical LRRC15-targeting ADC SIM0613.
- Boehringer Ingelheim’s €1.05 billion deal for rights outside Greater China to Simcere’s preclinical TL1A/IL-23 bispecific SIM0709 for inflammatory bowel disease.
Bottom line: Roche is not giving up on deeper B-cell depletion after its lupus setback. Instead, it is paying for another shot, this time with two B-cell targets instead of one.
